Oppenheimer Cautions Against Relmada Therapeutics Trial Optimism By Investing.com
© Reuters. By Sam Boughedda Shares of Relmada Therapeutics (NASDAQ:) plunged over 80% Thursday after the company announced that its drug to treat major depressive disorder did not achieve its primary endpoint. Relmada shares closed Wednesday’s session at $31.69 per share, but they are now down at $6.54. Following the news, Oppenheimer downgraded the shares …
Oppenheimer Cautions Against Relmada Therapeutics Trial Optimism By Investing.com Read More »